NL-OMON36478已完成不适用
Effect of aminobisphosphonates and statins on circulating Vgamma9Vdelta2-T cells - ABP statins study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-patients with an indication for intravenous treatment with an aminobisphosphonate because of bone metastases of a malignant tumor.
- •-WHO 0, 1, 2 performance score
排除标准
- •-WHO 3, 4 performance score
- •-prior or current use of aminobisphosphonates
- •-immunosuppressive medication (NSAID allowed)
- •-chemotherapy and/or radiotherapy in 4 weeks prior to start of aminobisphosphonate administration
- •-renal insufficiency (creatinin clearance < 30 ml/min)
- •-liver enzyme abnormalities: -bilirubin > 1.5 times ULN (upper limit of normal)
- •-ASAT or ALAT > 2.5 times ULN (in absence of livermetastases)
- •-ASAT or ALAT > 5 times ULN (in presence of livermetastases)
- •-concomitant use of strong inhibitors of CYP3A4, such as itraconazol, ketoconazol, erytromycin, claritromycin, hiv-protease inhibitors or grapefruit juice is contra-indicated.
研究者
相似试验
进行中（未招募）
不适用
Effect of aminobisphosphonates and statins on circulating Vy9Vd2-T cellspatients with malignant bone metastasesMedDRA version: 12.1Level: LLTClassification code 10005993Term: Bone metastasesEUCTR2010-018491-24-NLVrije Universiteit Medical Center
已完成
不适用
Invloed van aminobifosfonaten en statinen op circulerende Vgamma9Vdelta2-T cellen.Ossaal gemetastaseerde maligniteitBone metastases of a malignant tumorNL-OMON26533Prof. dr. H.M.W. Verheul, MD, PhDHead Department of Medical OncologyVU University Medical CenterDe Boelelaan 11171081 HV AmsterdamThe NetherlandsTel: +31 (0)20-4444321/300Fax: + 31 (0)20-4444079Email: h.verheul@vumc.nl40
已完成
不适用
Effect of Aminobiphosphonates and Statins on Circulating Vgamma9Vdelta2-T CellsBone Metastases of a Malignant TumorNCT01179464Amsterdam UMC, location VUmc19
已完成
不适用
Effects of aminobisphosphonates and thiazides in patients with osteopenia / osteoporosis, hypercalciuria and recurring renal calcium lithiasisBone mineral density loss and renal calcium stonesMusculoskeletal DiseasesOther osteoporosisISRCTN70158709San Cecilio University Hospital (Spain)70
进行中（未招募）
1 期
Statin- and bisphosphonate treatment in patients with the Philadelphia-negative chronic myeloproliferative neoplasms - essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis.The Philadelphia-negative chronic myeloproliferative neoplasms: Essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis.MedDRA version: 19.0Level: LLTClassification code 10028577Term: Myeloproliferative disorder NOSSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10028576Term: Myeloproliferative disorderSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10074692Term: Post essential thrombocythaemia myelofibrosisSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10028538Term: Myelofibrosis with myelometaplasiaSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10015495Term: Essential thrombocytosisSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10015494Term: Essential thrombocythemiaSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10013238Term: Disorder myeloproliferativeSystem Organ Class: 100000004864EUCTR2016-001406-42-DKHæmatologisk Afdeling, Sjælland Sygehus, Roskilde100